Navigation Links
Landmark Study Published in the New England Journal of Medicine,Shows Important Benefits of Eprodisate (KIACTA) Treatment for,Patients with Amyloid A (AA) Amyloidosis

ECUBLENS, SWITZERLAND, June 07, 2007 /PRNewswire-FirstCall/ - Neurochem (International) Limited (Neurochem), a wholly-owned subsidiary of Neurochem Inc. , announces that the New England Journal of Medicine (NEJM) published the results of the "Eprodisate For AA Amyloidosis Trial" (EFAAT), recognized as a landmark clinical trial in the search for a treatment of AA amyloidosis. The results of the Phase II/III clinical trial for eprodisate (KIACTA(TM)) demonstrate that this product candidate offers important clinical benefits to patients by reducing the progression of AA amyloidosis-associated renal disease. The results from the EFAAT have been submitted to the U.S. Food and Drug Administration, the European Medicines Agency and Swissmedic in support of applications for marketing approval of eprodisate (KIACTA(TM)) for the treatment of AA amyloidosis, a disease which remains today without a specific treatment.

The print issue of the publication will be available in the June 7, 2007 issue of the NEJM. The article entitled "Eprodisate for the Treatment of Renal Disease in AA Amyloidosis" is accessible online, and can be found at www.nejm.org under the "Current Issue" section of the Web site.

"These results show clinically important benefits for patients suffering from this disabling and potentially fatal disease," said Dr. Laura Dember, nephrologist and Associate Professor of Medicine, School of Medicine, and the lead author of the New England Journal of Medicine article reporting the results of the Phase II/III clinical trial for eprodisate (KIACTA(TM)). "Our treatment approach, up to this point, has been limited to controlling the inflammatory condition that underlies the development of AA amyloidosis. However, for many patients such efforts are unsuccessful and amyloid formation continues. KIACTA(TM) is the first product candidate designed to target
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Neurologix Announces Publication of Landmark Gene Therapy Study Demonstrating Safety and Statistically Significant Improvement in Patients With Advanced Parkinsons Disease
2. MEDIA ADVISORY: Subsets of Landmark Diabetes Trials Investigating MacroVascular Outcomes Presented at the American Diabetes Association 67th Scientific Sessions
3. Geron Corp. Licensee TA Sciences Announces Landmark 7/07/07 Teleconference to Answer Questions About TA-65, Their Telomerase Activator With Proven Age Management Benefits
4. Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events in Landmark Jikei Heart Study
5. Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events in Landmark Jikei Heart Study
6. Landmark Findings From ECLIPSE Program Show Improved Control of Perioperative Hypertension Reduces Risk of Death In Cardiac Surgery
7. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
8. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
9. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
10. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
11. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
Post Your Comments:
(Date:5/15/2008)...acy Clinical Data from Prostate, Colorectal and Ov...Company to Hold Investor Event on Sun., June 1 wit..., May 15 /- Poniard,Pharmac...al company focused,on oncology, today announced th...al trials of picoplatin, in various tumor types an...
(Date:5/15/2008)...ctions demonstrated in Blacks, Hispanics/Latinos, ...dividuals, PARSIPPANY, N.J., May 15 /PRNewswire/ ... presented at the American Society of,Hypertension...08) in New,Orleans demonstrated that the powerful ...an medoxomil) safely and effectively helped,patien...
(Date:5/15/2008).../- CenterWatch, a publishing and,info...h about clinical,trials, finds that investigative ...ic data capture) systems. More than 75% of respond... they had been trained on three or more,EDC system...ctiveness of,their EDC training had improved., St...
(Date:5/15/2008)...ected soon after CEA Trial data reports in third q...RANCISCO, May 15 /- VIA Pha...gy company focused on the development of,compounds...unced today that,it has completed patient enrollme... ACS study is one of three Phase 2 trials investig...
Breaking Medicine Technology:Poniard to Present Clinical Data From Picoplatin Trials in Multiple Tumor Types at American Society of Clinical Oncology 2008 Annual Meeting 2Poniard to Present Clinical Data From Picoplatin Trials in Multiple Tumor Types at American Society of Clinical Oncology 2008 Annual Meeting 3Poniard to Present Clinical Data From Picoplatin Trials in Multiple Tumor Types at American Society of Clinical Oncology 2008 Annual Meeting 4Poniard to Present Clinical Data From Picoplatin Trials in Multiple Tumor Types at American Society of Clinical Oncology 2008 Annual Meeting 5Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 2Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 3Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 4Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 5Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 6Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 7CenterWatch Releases State of the Clinical Trials Industry 2008 - A Key Industry Resource for Market Research and Competitive Intelligence 2VIA Pharmaceuticals Completes Enrollment in Phase 2 Acute Coronary Syndrome (ACS) Trial 2VIA Pharmaceuticals Completes Enrollment in Phase 2 Acute Coronary Syndrome (ACS) Trial 3VIA Pharmaceuticals Completes Enrollment in Phase 2 Acute Coronary Syndrome (ACS) Trial 4VIA Pharmaceuticals Completes Enrollment in Phase 2 Acute Coronary Syndrome (ACS) Trial 5Lotus Blossom Consulting Announces E Book on Infertility Treatment Financing 5637 1Lotus Blossom Consulting Announces E Book on Infertility Treatment Financing 5637 2A maternal link to Alzheimers disease 5633 1A maternal link to Alzheimers disease 5633 2A maternal link to Alzheimers disease 5633 3Synvista Announces New Data Showing Haptoglobin Type Predicts Effectiveness of Tight Glycemic Control on Cardiovascular Outcomes in Patients with Diab 770 1Synvista Announces New Data Showing Haptoglobin Type Predicts Effectiveness of Tight Glycemic Control on Cardiovascular Outcomes in Patients with Diab 770 2Synvista Announces New Data Showing Haptoglobin Type Predicts Effectiveness of Tight Glycemic Control on Cardiovascular Outcomes in Patients with Diab 770 3Data Presented at the American Heart Association Scientific Sessions 2007 Demonstrated Increased HDL with ACTOS 28R 29 28pioglitazone HCl 29 Slowed t 766 1Data Presented at the American Heart Association Scientific Sessions 2007 Demonstrated Increased HDL with ACTOS 28R 29 28pioglitazone HCl 29 Slowed t 766 2Data Presented at the American Heart Association Scientific Sessions 2007 Demonstrated Increased HDL with ACTOS 28R 29 28pioglitazone HCl 29 Slowed t 766 3
...SYDNEY, Australia 24 April 2007. Giaconda Ltd (ASX...dministration (FDA) has,approved the Company,s Inv...inical development of MyocondaR to treat patients ...vium spp,paratuberculosis (MAP). , ,The Company un...,first therapy to be submitted to the FDA for this...
... ROCKVILLE, Md., April 18, 2007--Due to water dama...en forced to change the,location for the upcoming ...l 24, 2007 to discuss new drug application for,mar... to be held at,the FDA, Center for Drug Evaluation...Room, 5630 Fishers Lane, in Rockville, MD, the,mee...
Other Medicine Technology:FDA approves MyocondaR IND for MAP in Crohn's Disease 2FDA approves MyocondaR IND for MAP in Crohn's Disease 3FDA approves MyocondaR IND for MAP in Crohn's Disease 4FDA Announces Change of Location Notice for Upcoming Advisory,Committee Meeting 2
(Date:5/17/2008)...ed Spokesperson for Education Campaign on Behalf o...teinase Inhibitor (Human) Augmentation ..., May 17 /PRNewswire/ -- Melissa Biggs, a fashion,...recently named,spokesperson for an education campa...ans to get tested for alpha-1 antitrypsin (AAT) de...
(Date:5/16/2008)NEW YORK, May 16 /PRNewswire/ -- There,s more to a healthy mouth than,flashing a set of pearly whites. Here,s the scoop on America,s oral care,habits - and what it means for our overall health.,
(Date:5/16/2008)...g Campaign to Emphasize the Importance of Oral and...ire/ -- National dental insurer United,Concordia D...boration,between Oral Health America and the Briti...nce of oral health to overall health. Beginning Ma... States for the first time,making it the largest ...
(Date:5/16/2008)...s chronic disease sufferers gain benefit from calc...(HealthDay News) -- Taking activated vitamin D may... severe chronic kidney disease by about one quarte...tudy of more than 1,400 patients, those being trea...amin D, had their overall risk of death lowered by...
Breaking Medicine News(10 mins):Health News:Melissa Biggs, Fashion Designer and Former Baywatch Actress, Teams with CSL Behring to Raise Awareness of Alpha-1 Antitrypsin Deficiency, a Commonly Misdiagnosed Respiratory Disease 2Health News:Melissa Biggs, Fashion Designer and Former Baywatch Actress, Teams with CSL Behring to Raise Awareness of Alpha-1 Antitrypsin Deficiency, a Commonly Misdiagnosed Respiratory Disease 3Health News:Melissa Biggs, Fashion Designer and Former Baywatch Actress, Teams with CSL Behring to Raise Awareness of Alpha-1 Antitrypsin Deficiency, a Commonly Misdiagnosed Respiratory Disease 4Health News:Melissa Biggs, Fashion Designer and Former Baywatch Actress, Teams with CSL Behring to Raise Awareness of Alpha-1 Antitrypsin Deficiency, a Commonly Misdiagnosed Respiratory Disease 5Health News:United Concordia Dental Celebrates National Smile Month 2Health News:Vitamin D Use Linked to Lower Mortality in Kidney Patients 2
...may be the cause of migraines and severe headaches...dy mass //index on frequency, and severity of head...adaches are more common in obese people than those...ers had taken the physical history of the particip...
...ts have found out that increased calcium intake by...may increase the risk of Parkinson’s disease. Park...m. Some of its symptoms are muscle tremors, muscle...ty, stooped posture, slow voluntary movements, and...
...ug AVP-923 is all set to provide relief to people ...clerosis, said the researchers from University of ...s is a chronic neurological disease of the central...he brain and spinal cord and medication till date ...
...was undertaken to find out how to elevate the func...rom arthritis // by the researchers of Feinberg Sc...e study of age 65 yrs and old with arthritis. Func...y to do tasks pertaining to daily living and speci...
Other Medicine News:
...oratories is a national reference laboratory and a...h and development. ARUP offers an extensive test m...clinical and anatomic pathology. Owned by the Univ... more than half of the nation's university teachin...
...oratories is a national reference laboratory and a...h and development. ARUP offers an extensive test m...clinical and anatomic pathology. Owned by the Univ... more than half of the nation's university teachin...
...oratories is a national reference laboratory and a...h and development. ARUP offers an extensive test m...clinical and anatomic pathology. Owned by the Univ... more than half of the nation's university teachin...
...oratories is a national reference laboratory and a...h and development. ARUP offers an extensive test m...clinical and anatomic pathology. Owned by the Univ... more than half of the nation's university teachin...
Medicine Products: